阻断卡利克林-基宁通路的反意义疗法在COVID-19中:ASKCOV随机对照试验
Fernando G Zampieri1, Glauco Adrieno Westphal2, Maria Adelaide Dos Santos3
1HCOR Research Institute, São Paulo, SP, Brazil; Department of Critical Care Medicine, University of Alberta, Edmonton, Canada.
Journal of critical care
|August 3, 2024
概括
针对kallikrein-kinin通路的反意义疗法没有改善住院COVID-19患者的结果. 该研究发现,在接受治疗和安慰剂组之间,没有氧气支持的情况下活着的日子没有显著差异.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 临床试验 临床试验
背景情况:
- 卡利克林-基宁通路在炎症和血管透性中起作用,可能导致COVID-19的严重程度.
- 反意义疗法提供了一种有针对性的方法来调节特定的生物通路.
研究的目的:
- 评估抗感觉疗法 (ISIS721744) 在住院COVID-19患者中阻断kallikrein-kinin通路的疗效.
- 确定这种干预措施是否改善了临床结果,特别是活着和没有氧气支持的日子.
主要方法:
- 这是一项随机,双盲,安慰剂控制的试验,涉及111名需要补充氧气的住院COVID-19患者.
- 患者接受了ISIS721744单次皮下注射剂或安慰剂.
- 主要结局是几天活着,没有氧气支持 (DAFOR15).
主要成果:
- 在ISIS721744组 (5.9天) 和安慰剂组 (7.7天) 之间没有观察到DAFOR15的显著差异.
- 平均差异为-0.65天,p值为0.520,表明没有统计学上显著的好处.
- 二级和探索性终点也没有显示出显著的改善.
结论:
- 针对kallikrein-kinin通路的反意义疗法在COVID-19患者的临床益处没有在疫情的初期阶段证明.
- 可能需要进一步的研究来探索其他治疗点或患者群体.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
517
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
517
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
569
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
569
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
151
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
151
siRNA - Small Interfering RNAs
16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
502
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
502


